“We all love to buy pharma stocks when they release positive clinical data, but they can also be solid choices for investors looking for businesses to buy on the dip,” advises the author of today’s article. He proceeds to highlight two pharma stocks – “a company developing neuroscience drugs and another that’s developing therapies for genetic diseases” – and why they may be strong “buy the dip” candidates right now. For more, CLICK HERE.